LONDON/COPENHAGEN, June 23 (Reuters) - Shares in Novo Nordisk (NOVOb.CO), opens new tab fell as much ... weekend that showed no safety issues in a mid-stage trial of its oral weight-loss candidate ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Drug to initially be offered to people with BMI over 40 with at least four other health problems linked to obesity ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...